1175 YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability

• Xiang Guo,
• Lei Zhang,
• Jing Zhang,
• Yi Yang,
• Baihong Liu,
• W Frank An,
• Chaoshe Guo,
• Yanfei Han

Affiliations

Xiang Guo

2Eucure (Beijing) Biopharma Co., Ltd., Beijing, China

Lei Zhang

Clinical Medical Research Center, Children`s Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China

Jing Zhang

associate professor

Yi Yang

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Baihong Liu

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

W Frank An

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Chaoshe Guo

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Yanfei Han

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China